Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) – Drugs in Development, 2021

Global Markets Direct’s, ‘Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) – Drugs in Development, 2021’, provides in depth analysis on Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas under Central Nervous System, Cardiovascular, Gastrointestinal and Oncology development targeting Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)

– The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects

– The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

180 Life Corp

AlphaCognition Inc

AstraZeneca Plc

Bionomics Ltd

Bristol-Myers Squibb Co

DanPET AB

Epigen Biosciences Inc

Lupin Ltd

Merck & Co Inc

Neuro Bio Ltd

SK Biopharmaceuticals Co Ltd

Vanda Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) – Overview

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) – Companies Involved in Therapeutics Development

180 Life Corp

AlphaCognition Inc

AstraZeneca Plc

Bionomics Ltd

Bristol-Myers Squibb Co

DanPET AB

Epigen Biosciences Inc

Lupin Ltd

Merck & Co Inc

Neuro Bio Ltd

SK Biopharmaceuticals Co Ltd

Vanda Pharmaceuticals Inc

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) – Drug Profiles

ALPHA-1062 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVL-3288 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVL-8168 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-0328 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-910731 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNC-210 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNC-375 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EPGN-1137 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LL-00066471 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NBP-14 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NS-12877 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKL-20540 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize CHRNA7 for Ulcerative Colitis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize CHRNA7 for Central Nervous System – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VQW-765 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) – Dormant Products

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) – Discontinued Products

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) – Product Development Milestones

Featured News & Press Releases

Nov 01, 2021: Bionomics Receives FDA clearance of IND for evaluation of BNC210 in a phase 2 social anxiety disorder PREVAIL study

Nov 01, 2021: Bionomics gets FDA approval for trial of social anxiety disorder treatment

Sep 20, 2021: Bionomics prepares BNC210 for start of phase 2 acute treatment of social anxiety disorder trial

Sep 09, 2021: Alpha Cognition to Webcast Live on ALPHA-1062 at Life Sciences Investor Forum September 16th

Sep 07, 2021: Alpha Cognition announces the acceptance of its US FDA investigational new drug application (IND) for lead candidate, ALPHA-1062 for mild to moderate Alzheimer’s Disease

Jul 08, 2021: Novamind selected as research site for Bionomics' PTSD clinical trial

Jul 06, 2021: Bionomics initiates phase 2b ATTUNE study of BNC210 in PTSD

May 10, 2021: Bionomics expanding BNC210 for acute treatment of social anxiety disorder in addition to phase 2b trial for post traumatic stress disorder

Apr 30, 2021: Agilex Biolabs congratulates Bionomics on BNC210 PK results

Apr 27, 2021: Alpha Cognition announces Ms. Colleen Johns as SVP, product development further strengthening the ALPHA-1062 drug commercialization team

Apr 12, 2021: Alpha Cognition announces Mr. Michael McFadden as chief executive officer and realignment of leadership team for next stage of alpha-1062 drug development

Feb 22, 2021: Positive BNC210 7-Day dosing pharmacokinetic study exceeds blood exposure projected for phase 2b PTSD trial

Jan 18, 2021: Publication of positive BNC210 phase 2a data in generalised anxiety disorder patients

Jan 07, 2021: Bionomics presenting at virtual H.C. Wainwright Bioconnect 2021 conference

Jan 04, 2021: Bionomics initiates 7-day dosing pharmacokinetic study of BNC210 tablet formulation

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by 180 Life Corp, 2021

Pipeline by AlphaCognition Inc, 2021

Pipeline by AstraZeneca Plc, 2021

Pipeline by Bionomics Ltd, 2021

Pipeline by Bristol-Myers Squibb Co, 2021

Pipeline by DanPET AB, 2021

Pipeline by Epigen Biosciences Inc, 2021

Pipeline by Lupin Ltd, 2021

Pipeline by Merck & Co Inc, 2021

Pipeline by Neuro Bio Ltd, 2021

Pipeline by SK Biopharmaceuticals Co Ltd, 2021

Pipeline by Vanda Pharmaceuticals Inc, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Dormant Products, 2021 (Contd..2)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports